Published works

Pharmacology

Pharmacology

  • 136Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice.Naunyn Schmiedebergs Arch Pharmacol.2018PubMed
  • 129Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner.BMJ Open Diabetes Res Care.2017PubMed
  • 126Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.Hypertens Res.2017PubMed
  • 125Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression. Eur J Pharmacol. 2017PubMed
  • 115The protective effect of human atrial natriuretic peptide on renal damage during cardiac surgery.J Anesth.2016PubMed
  • 113The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.Clin Exp Nephrol.2016PubMed
  • 107Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.Cardiovasc Diabetol.15(1): 76, 2016.PubMed
  • 106Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.Am J Physiol Renal Physiol.310(11):F1366-1376, 2016.PubMed
  • 96Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats.Physiol Rep.3(12), 2015.PubMed
  • 91Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.Scand J Clin Lab Invest.75(5): 421-427, 2015.PubMed
  • 89Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment? Nephrology.10(4):e0122212, 2015.PubMed
  • 85Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.Clin Exp Nephrol.19(6): 1044-1053, 2015.PubMed
  • 62A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.Am J Physiol Renal Physiol.305(12): F1796-1803, 2013.PubMed
  • 58Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.Diabet Med.29(8): e184-190, 2012.PubMed
  • 56Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.Hypertens Res.35(11): 1058-1062, 2012.PubMed
  • 51Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).Internal Medicine.50(12): 1273-1278, 2011.PubMed
  • 50Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.Hypertens Res .34: 935-941, 2011.PubMed
  • 39Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.Am J Med Sci.339(2): 157-163, 2010.PubMed
  • 38Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.Kidney Blood Press Res.33(3): 213-220, 2010.PubMed
  • 37Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.Eur J Clin Invest.40(9): 790-796, 2010.PubMed
  • 35Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.Am J Pathol.174(4): 1203-1211, 2009.PubMed
  • 33Tubular and glomerular injury in diabetes and the impact of ACE inhibition.Diabetes Care.32(9): 1684-1688, 2009.PubMed
  • 26Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.Kidney Int.73(12): 1374-1384, 2008.PubMed
  • 25Renoprotective effect of telmisartan in patients with chronic kidney disease.Clin Exp Hypertens.30(7): 662-672, 2008.PubMed
  • 24Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.Clin Nephrol.70(5): 385-392, 2008.PubMed
  • 21Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.Diabetologia.50(2): 490-492, 2007.PubMed
  • 20Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.Am J Med Sci.333(6): 321-326, 2007.PubMed
  • 19Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.Am J Hypertens.20(11): 1195-1201, 2007.PubMed
  • 15Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.Clin Nephrol.65(1): 1-6, 2006.PubMed
  • 14Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.Diabetes Metab Res Rev.22(5): 385-389, 2006.PubMed
  • 13Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.Am J Nephrol.26(3): 276-280, 2006.PubMed
  • 12Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.Am J Nephrol.26(1): 82-86, 2006.PubMed
  • 7Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.TAm J Med Sci.330(4): 161-165, 2005.PubMed
  • 6Effect of Pitavastatin on Urinary Liver-Type Fatty Acid?Binding Protein Levels in Patients With Early Diabetic Nephropathy.Diabetes Care.28(11): 2728-2732, 2005.PubMed

Category

Download product leaflet

For nonclinical safety evaluation

Urinary L-FABP kits for Rat, Dog, Cat, Monkey and Pig are available for the purpose of monitoring drug nephrotoxicity and drug effectiveness.
Top ▲ Home ▶